(NASDAQ: ALGS) Aligos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.63%.
Aligos Therapeutics's earnings in 2026 is -$75,962,000.On average, 9 Wall Street analysts forecast ALGS's earnings for 2026 to be -$89,539,468, with the lowest ALGS earnings forecast at -$143,934,564, and the highest ALGS earnings forecast at -$35,013,237. On average, 9 Wall Street analysts forecast ALGS's earnings for 2027 to be -$54,192,772, with the lowest ALGS earnings forecast at -$71,587,613, and the highest ALGS earnings forecast at -$39,078,444.
In 2028, ALGS is forecast to generate -$29,490,550 in earnings, with the lowest earnings forecast at -$72,089,675 and the highest earnings forecast at $56,126,087.